en
Scientific article
French

Obstetrical Antiphospholipid Syndrome: From the Pathogenesis to the Clinical and Therapeutic Implications

Published inClinical & developmental immunology, vol. 2013, p. 1-9
Publication date2013
Abstract

Antiphospholipid syndrome (APS) is an acquired thrombophilia with clinical manifestations associated with the presence of antiphospholipid antibodies (aPL) in patient plasma. Obstetrical APS is a complex entity that may affect both mother and fetus throughout the entire pregnancy with high morbidity. Clinical complications are as various as recurrent fetal losses, stillbirth, intrauterine growth restriction (IUGR), and preeclampsia. Pathogenesis of aPL targets trophoblastic cells directly, mainly via proapoptotic, proinflammatory mechanisms, and uncontrolled immunomodulatory responses. Actual first-line treatment is limited to low-dose aspirin (LDA) and low-molecular weight heparin (LMWH) and still failed in 30% of the cases. APS pregnancies should be a major field in obstetrical research, and new therapeutics are still in progress.

Keywords
  • Antiphospholipid
  • Trophoblast
  • Obstetrical
Citation (ISO format)
MARCHETTI, Tess, COHEN, Marie-Benoîte, DE MOERLOOSE, Philippe. Obstetrical Antiphospholipid Syndrome: From the Pathogenesis to the Clinical and Therapeutic Implications. In: Clinical & developmental immunology, 2013, vol. 2013, p. 1–9. doi: 10.1155/2013/159124
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1740-2522
574views
2downloads

Technical informations

Creation07/14/2014 4:19:00 PM
First validation07/14/2014 4:19:00 PM
Update time03/14/2023 9:34:11 PM
Status update03/14/2023 9:34:11 PM
Last indexation01/16/2024 11:44:51 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack